MeiraGTx Q1 net loss widens to $0.70 per share; Phase 3 XLRP trial actively dosing

MeiraGTx Holdings plc

2022-Q1 EPS reported -$0.70 revenue$5,633,000

Net loss of $31.0M ($0.70 per share) vs $23.6M ($0.54) in Q1 2021; R&D spend rose to $23.1M.
Cash and equivalents of $114M plus $13.1M Janssen receivable; runway into Q4 2023.
Phase 3 Lumeos trial of botaretigene sparoparvovec for XLRP actively dosing patients; BLA submission targeted in 2024.
Phase 1 AQUAx trial for radiation-induced xerostomia completed all cohorts; Phase 2 planned by year-end 2022.
IND for AAV-GAD in Parkinson's filed May 2022; riboswitch platform advancing to first-in-human studies by end of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.